

JOURNÉES SCIENTIFIQUES
Nantes Université

| 27 mai 2025

Participez au colloque :

Des biomarqueurs aux thérapies innovantes dans les cancers à haut risque

Inscrivez-vous jusqu'au 11 mai sur js.univ-nantes.fr



COLLOQUE

N°16

From Biomarkers to Innovative Therapies in High-Risk Cancers

8h30 Registration

8h45 **SESSION 1 : Next-generation therapies in oncology & hematology**

Lecture: The saga of therapeutic antibody development in cancer *

- Prof. Daniel Olive, professor of immunology, head of the Immunity and Cancer team, Cancer Research Center of Marseille

9h30 **Engage them! Efficacy and mechanisms of action of bispecific antibodies in immunotherapies**

- Prof. Cyrille Touzeau, hematologist, CHU Nantes
- Dr. Nils Giordano, postdoctoral researcher, CRCI²NA
- Dr. Catherine Pellat-Deceunynck, head of the Molecular Vulnerabilities of Tumor Escape in mature B-cell Malignancies team, CRCI²NA

10h05 **Breaking tumour resistance with the rise of targeted therapies: from scientific innovation to medical application**

- Prof. Benoît Tessoulin, hematologist, CHU Nantes
- Dr. David Chiron, head of the Molecular Vulnerabilities of Tumor Escape in mature B-cell Malignancies team, CRCI²NA

10h35 **Break**

10h50 **CAR-T cells in brain tumours**

- Dr. Claire Pecqueur, head of the Petry team, CRCI²NA
- Dr. Béatrice Clémenceau, research engineer in Manipulation of Lymphocytes for Immunotherapy team, CRCI²NA

11h20 **SESSION 2: Theranostics & targeted radionuclide therapies**

Shaping the future of glioblastoma treatment: locoregional At-211 radiotherapy targeting Syndecan-1 leads durable remission & immune memory

- Dr. Emmanuel Garcion, head of the Innovative local alternatives in the medical treatment of glioblastoma team, CRCI²NA

11h35 **Prospects for radiotheranostics in prostate cancer**

- Dr. Clément Bailly, nuclear physician, CHU Nantes
- Prof. Stéphane Supiot, radiation oncologist, ICO
- Prof. Jérôme Rigaud, head of the urology department, CHU Nantes

12h15 **Targeting CXCR4 in hematological diseases**

- Prof. Caroline Bodet-Milin, nuclear physician, CHU Nantes

12h30 **LUNCH**

14h00 **Lecture: Radioligand therapy and breast cancer: challenges and new horizons**

- Prof. Désirée Deandreis, chief of the nuclear medicine division, Institut Gustave Roussy

14h40

SESSION 3: Imaging & AI-driven biomarker discovery

Interest of machine learning in PET for hematologic malignancies: from early developments to today

- Dr. Thomas Carlier, medical physicist in nuclear medicine, CHU de Nantes
- Oriane Thierry, PhD student LS2N

15h10

Using predictive models in radiotherapy: towards personalised medicine

- Dr. Tanguy Perennec, radiation oncologist, head of artificial intelligence unit, ICO

15h30

Break

15h45

SESSION 4: Biomarkers & therapy response: new Insights in oncology & hematology

FLT3-Ligand and IL-6: impact on acute leukemia management

- Prof. Joëlle Gaschet, nuclear oncology team, CRCI²NA, Nantes Université
- Dr. Pierre Peterlin, hematologist, CHU Nantes

16h15

Epigenetic/Epitranscriptomic biomarkers in lung cancer therapy

- Dr. Judith Raimbourg, medical oncologist, ICO
- Dr. Pierre François Cartron, researcher in Stress Adaptation and Tumor Escape team, CRCI²NA / ICO

16h45

EV-Score as a biomarker: exploration of plasma extracellular vesicles from HR+ metastatic breast cancer patients under CDK4/6 inhibitors treatment

- Prof. Jean-Sébastien Frenel, medical oncologist, ICO
- Dr. Laetitia Guével, Signaling in Oncogenesis, Angiogenesis and Permeability team, CRCI²NA, Nantes Université

17h15

End of the conference

*videoconference presentation